Ferroni P, Milenic D E, Schlom J, Colcher D
Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
J Clin Lab Anal. 1990;4(6):465-73. doi: 10.1002/jcla.1860040614.
The administration of xenogenic monoclonal antibodies (MAbs) leads in many cases to a host immune response represented by the generation of antibodies that can be directed against allotypic, isotypic, and idiotypic determinants present on the xenogeneic MAb. Anti-idiotypic antibodies (Ab2s) can be detected by measuring their specific reactivity in sandwich assays using their ability to cross-link labeled Ab1 to Ab1 attached to a solid phase; however, when the MAb used for these studies reacts with a multideterminant tumor-associated antigen found in the circulation (e.g., TAG-72), the utility of these anti-idiotype assays may be limited. To determine the levels of anti-idiotypic antibodies that could be detected in patients undergoing MAb B72.3-based immunodiagnostic and immunotherapeutic protocols, we investigated the ability of a solid-phase sandwich radioimmunoassay (RIA) to detect anti-idiotypic antibodies raised against B72.3. Furthermore, to overcome the interference of circulating TAG-72 and/or antibodies to allotypic and isotypic determinants in the evaluation of an anti-idiotypic response, we developed a methodology using CC49-coated resin to absorb the interfering molecules (CC49 is a second anti-TAG-72 MAb). Under the conditions established, all of the TAG-72 antigen was removed by adsorption with MAb CC49. Furthermore, since the treatment used an isotype-identical murine MAb, the binding due to the anti-mouse antibodies, other than the anti-idiotype, was completely abolished after a treatment with MAb CC49, leaving only the anti-idiotype component.(ABSTRACT TRUNCATED AT 250 WORDS)